Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK joins global vaccine alliance to help prevent millions of children from contracting pneumococcal disease in the world’s poorest countries
Unique finance mechanism ensures vaccinations will begin in 2010 - Up to 300 million doses to be supplied over ten years.
-
GSK announces succession plan for leadership of Consumer Healthcare business
Emma Walmsley appointed President, Consumer Healthcare Europe and President Designate, Worldwide Consumer Healthcare
-
GlaxoSmithKline statement on new information relating to manufacture of Rotarix (rotavirus vaccine)
GlaxoSmithKline (GSK) today confirmed that it has notified regulatory authorities of the presence of material from a virus called PCV-1.
-
GlaxoSmithKline announces Swiss approval of Duodart®
The first fixed dose combination medicine for benign prostatic hyperplasia
-
GlaxoSmithKline commences Relovair Phase III asthma programme
GlaxoSmithKline (GSK) announced today that the first asthma patient has commenced treatment with Relovair.
-
GSK publishes 2009 Corporate Responsibility Report
In its 2009 Corporate Responsibility Report published online today, GSK reiterated its commitment to running its business responsibly.
-
GlaxoSmithKline receives marketing authorisation in the EU for Revolade® (eltrombopag)
GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted marketing authorisation for Revolade.
-
GSK commences succession plan for management of vaccines business
GlaxoSmithKline (GSK) today announced management changes related to its Vaccines business as part of a planned succession strategy.
-
GSK CEO Andrew Witty dedicates albendazole facility in Nashik to WHO’s Global Programme to Eliminate LF
(GSK) CEO Andrew Witty today dedicated a new production facility at its Nashik site in India to the manufacture of albendazole.
-
GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia
GSK responded to the released Senate Committee on Finance January 2010 Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia.
-
GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia
The Staff Report of the Senate Committee on Finance draws conclusions on the safety of Avandia (rosiglitazone).
-
GSK rejects conclusions reported in The New York Times story on Avandia
GlaxoSmithKline (GSK) rejects the conclusions about the safety of Avandia (rosiglitazone) reported in New York Times story.
-
GSK receives positive opinions in Europe for Tyverb® (lapatinib) and Votrient™ (pazopanib)
GSK announced today that CHMP has issued two positive opinions in the European Union for two of its cancer medicines.
-
GSK statement on FDA’s proposed label revisions for some asthma medicines
GSK is reviewing label changes proposed today by FDA for asthma medications containing long-acting beta-agonists (LABAs).
-
GSK Consumer Healthcare warns consumers of potential health risks associated with long-term excessive use of zinc-containing denture adhesives
Because the safety and health of our consumers is our primary concern.
-
GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant™ (GSK1838262/XP13512) for RLS
GSK and XNPT received a Complete Response letter from FDA regarding NDA for gabapentin enacarbil) Extended-Release Tablets.
-
GSK launches new specialist unit to research and develop medicines for rare diseases
GSK today announces the formation of a new standalone unit specialising in the development and commercialisation of medicines.
-
GSK announces appointment of Philippe Fauchet as President of GSK Japan
GSK today announces the appointment of Philippe Fauchet as President of GSK Japan.
-
Results announcement for the fourth quarter 2009
See the quarterly results page for more information
-
GSK’s Tykerb® receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancer
GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval.
